SUMMARY
Bovine pericardial patches have become increasingly popular for carotid repair thanks to their advantages over synthetic patches, including superior bio-compatibility, reduced suture bleeding and better surgical handling, without restrictions on ultrasound tests. However, until now, biomaterials have been linked to problems including toxicity, immune reactions and calcification. Engineered using APADT® technology, the VascuCel® bio-scaffold provides the benefits of a biopatch while avoiding the trade-offs: ADAPT® scaffolds are completely acellular, thoroughly crosslinked and fully detoxified and sterilised, providing healing through new tissue growth, minimised risk of re-operation for the patient, and an optimised procedure for the surgeon.
http://www.admedus.com/wp-content/u.../Admedus-VascuCel-review-Nov-2016-final-1.pdf
Edit: Mods please correct title to VascuCel - a typo!
- Forums
- ASX - By Stock
- AVR
- VacuCel Clinical Literature Review
VacuCel Clinical Literature Review
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVR (ASX) to my watchlist
|
|||||
Last
$13.14 |
Change
0.140(1.08%) |
Mkt cap ! $277.7M |
Open | High | Low | Value | Volume |
$13.20 | $13.50 | $13.14 | $559.5K | 42.05K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 1180 | $13.00 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$13.35 | 500 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 680 | 13.000 |
1 | 1000 | 12.950 |
2 | 67 | 12.900 |
1 | 1000 | 12.800 |
1 | 37 | 12.000 |
Price($) | Vol. | No. |
---|---|---|
13.350 | 500 | 1 |
13.500 | 2000 | 1 |
13.510 | 46 | 1 |
13.900 | 300 | 1 |
14.440 | 25 | 1 |
Last trade - 16.10pm 12/09/2024 (20 minute delay) ? |
Featured News
AVR (ASX) Chart |